Video

Dr. Helfand on how genomic testing provides real-time status of prostate tumor

Author(s):

Urology Times staff
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how genomic testing is a great tool for identifying “what is going on in the tumor ‘right now.’”

      Related Videos
      Expert on prostate cancer
      Closing Thoughts on Urology Practice Management and Treatment of Advanced Prostate Cancer
      Expert on prostate cancer
      Overcoming Staffing Challenges and Turnover in Urology Practices
      Expert on prostate cancer
      Scheduling and Administering Leuprolide: Key Challenges and Practical Solutions
      Experts on prostate cancer
      The Impact of Telehealth on Treatment Selection in Advanced Prostate Cancer
      Complementary use of mpMRI and genomic testing in prostate cancer
      Complementary use of mpMRI and genomic testing in prostate cancer
      How genomic testing can address accuracy issues with PSA screening and monitoring
      How genomic testing can address accuracy issues with PSA screening and monitoring
      Dr. Helfand on the increasing role of genomic testing in prostate cancer
      Dr. Helfand on the increasing role of genomic testing in prostate cancer
      Around the Practice July 21, 2021: Bladder Cancer Cases
      Around the Practice July 21, 2021: Bladder Cancer Cases
      Genetic, Genomic Testing in Heavily Treated, Metastatic Castrate-Resistant Prostate Cancer
      Genetic, Genomic Testing in Heavily Treated, Metastatic Castrate-Resistant Prostate Cancer
      Genetic, Genomic Testing in Newly Diagnosed, High-Grade, High-Risk Prostate Cancer
      Genetic, Genomic Testing in Newly Diagnosed, High-Grade, High-Risk Prostate Cancer
      Related Content
      Around the Practice: The Management of Biochemical Recurrence in Prostate Cancer
      May 6th 2021

      Around the Practice: The Management of Biochemical Recurrence in Prostate Cancer

      This article reviews new imaging technologies that may improve early detection of biochemical recurrence after definitive treatment for prostate cancer. This article also features insights from oncology experts Raoul Concepcion, MD; Judd Moul, MD; Brian Helfand, MD; Munir Ghesani, MD.
      © 2025 MJH Life Sciences

      All rights reserved.